Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
← catalyst calendarNCT04550260 · readout in 315 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
640actual
Sites
133
Countries
Belgium, Brazil, Canada +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-19 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2020-09-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Esophageal Squamous Cell Carcinoma
Interventions
- Drug: Durvalumab — also filed as MEDI4736
- Drug: Placebo
- Drug: cisplatin + fluorouracil
- Drug: cisplatin + capecitabine
- Radiation: Radiation
Primary outcome
what the primary-completion date above is the date OFProgression free survival (PFS) per RECIST 1.1 as assessed by BICR
measured up to approximately 56 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed